Nebenwirkungen · Enhertu
Enhertu 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9
HOS-144502 · Präparat HOS-099200
The most common National Cancer Institute – Common Terminology Criteria for Adverse Events (NCI-CTCAE v.5.0) Grade 3 or 4 adverse reactions were neutropenia (18.5%), anaemia (9.9%), fatigue (8.2%), leukopenia (5.8%), thrombocytopenia (5.2%), nausea (4.8%), lymphopenia (4.2%), transaminases increased (3.7%), hypokalaemia (3.6%), diarrhoea (2.5%), vomiting (2.4%), decreased appetite (1.6%), pneumonia (1.4%) and ejection fraction decreased (1.0%). Grade 5 adverse reactions occurred in 1.1% of patients, including ILD/pneumonitis (1.0%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:27:00Z · SHA-256 3c4c744afc1ef29bbcad254e39bd7fd8b4be34bb4ddecf254258c2ab2c9863c8 · Passage 4258d92ac3372cdec079813aa0176f80db3310a2a64cd942ff58d072ff0947d7 · Zeichen 666–1204 im Abschnitt